{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:37:48Z","timestamp":1791581868447,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of sepetaprost, a novel dual FP\/EP3 receptor agonist, in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>ANGEL-J1 (NCT05495061) was a phase 3, randomised, investigator-masked, active-controlled, parallel-group, non-inferiority study across 49 sites in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with POAG or OHT were randomised 1:1 to topical sepetaprost 0.002% or latanoprost 0.005%, once daily for 3 months. The primary endpoint was change in mean diurnal intraocular pressure (IOP) from baseline at week 4 (non-inferiority margin, 1.5 mmHg); a key secondary endpoint was mean change in IOP from baseline over 3\u00a0months. Safety outcomes included the incidence of adverse drug reactions (ADRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 325 patients were randomised to sepetaprost (n=162) or latanoprost (n=163). In mixed model for repeated measures analyses, ANGEL-J1 met its primary endpoint; the least-squares mean (\u00b1 standard error) change in mean diurnal IOP from baseline at week 4 was \u22125.77\u00b10.16 mmHg in the sepetaprost group, which was non-inferior to \u22126.10\u00b10.16 mmHg in the latanoprost group (least-squares mean difference, 0.32\u00a0mmHg [95% confidence interval, \u22120.12, 0.77]). Non-inferiority for the key secondary endpoint was also established, with comparable mean reductions in IOP between groups maintained over 3 months. ADRs occurred in 59 patients (36.4%) receiving sepetaprost and 33 (20.2%) receiving latanoprost; the most common ADR was conjunctival hyperaemia (29.6% and 8.6%, respectively; mostly mild in severity).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with POAG or OHT, sepetaprost demonstrated IOP-lowering efficacy that was non-inferior to latanoprost, and an acceptable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10384-026-01350-3","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:57:28Z","timestamp":1781578648000},"page":"957-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-996X","authenticated-orcid":false,"given":"Masaru","family":"Inatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-1142","authenticated-orcid":false,"given":"Akiyasu","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Inai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5209-9131","authenticated-orcid":false,"given":"Raymund","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1350_CR1","doi-asserted-by":"publisher","first-page":"16067","DOI":"10.1038\/nrdp.2016.67","volume":"2","author":"RN Weinreb","year":"2016","unstructured":"Weinreb RN, Leung CK, Crowston JG, Medeiros FA, Friedman DS, Wiggs JL, et al. Primary open-angle glaucoma. Nat Rev Dis Primers. 2016;2:16067.","journal-title":"Nat Rev Dis Primers"},{"key":"1350_CR2","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to sight: an analysis for the global burden of disease study. Lancet Glob Health. 2021;9:e144\u201360.","journal-title":"Lancet Glob Health"},{"key":"1350_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s10792-024-03222-6","volume":"44","author":"W Chen","year":"2024","unstructured":"Chen W, Xu Y, Liu Z, Zhao J. Global, regional and national burden of glaucoma: an update analysis from the Global Burden of Disease Study 2019. Int Ophthalmol. 2024;44:234.","journal-title":"Int Ophthalmol"},{"key":"1350_CR4","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41433-024-02995-5","volume":"38","author":"Vision Loss Expert Group of the Global Burden of Disease Study","year":"2024","unstructured":"Vision Loss Expert Group of the Global Burden of Disease Study, GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by glaucoma: a meta-analysis from 2000 to 2020. Eye (Lond). 2024;38:2036\u201346.","journal-title":"Eye (Lond)"},{"key":"1350_CR5","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"1350_CR6","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, Suzuki Y, Abe H, Shirato S, et al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112:1661\u20139.","journal-title":"Ophthalmology"},{"key":"1350_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/tvst.11.11.11","volume":"11","author":"K Fujiwara","year":"2022","unstructured":"Fujiwara K, Yasuda M, Hata J, Nakano S, Hashimoto S, Ueda E, et al. Prevalence of glaucoma and its systemic risk factors in a general Japanese population: the Hisayama study. Transl Vis Sci Technol. 2022;11:11.","journal-title":"Transl Vis Sci Technol."},{"key":"1350_CR8","doi-asserted-by":"publisher","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open-angle glaucoma Preferred Practice Pattern\u00ae. Ophthalmology. 2021;128:P71-150.","journal-title":"Ophthalmology"},{"key":"1350_CR9","first-page":"1","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society. European Glaucoma Society terminology and guidelines for glaucoma, 5th Edition. Br J Ophthalmol. 2021;105:1\u2013169.","journal-title":"Br J Ophthalmol"},{"key":"1350_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, Nakamura M, Tanito M. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67:189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"key":"1350_CR11","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10384-024-01052-8","volume":"68","author":"K Inoue","year":"2024","unstructured":"Inoue K, Shiokawa M, Kunimatsu-Sanuki S, Kang J, Uraki T, Tomita G, et al. Three-year efficacy and safety of omidenepag isopropyl in patients with normal tension glaucoma. Jpn J Ophthalmol. 2024;68:206\u201310.","journal-title":"Jpn J Ophthalmol"},{"key":"1350_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ogla.2020.09.002","volume":"4","author":"GF Schwartz","year":"2021","unstructured":"Schwartz GF, Patel A, Naik R, Lunacsek O, Ogbonnaya A, Campbell J. Characteristics and treatment patterns of newly diagnosed open-angle glaucoma patients in the United States: an administrative database analysis. Ophthalmol Glaucoma. 2021;4:117\u201325.","journal-title":"Ophthalmol Glaucoma"},{"key":"1350_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/17469899.2019.1635456","volume":"14","author":"AL Robin","year":"2019","unstructured":"Robin AL, Muir KW. Medication adherence in patients with ocular hypertension or glaucoma. Exp Rev Ophthalmol. 2019;14:199\u2013210.","journal-title":"Exp Rev Ophthalmol"},{"key":"1350_CR14","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1167\/iovs.14-16181","volume":"56","author":"S Yamane","year":"2015","unstructured":"Yamane S, Karakawa T, Nakayama S, Nagai K, Moriyuki K, Neki S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci. 2015;56:2547\u201352.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1350_CR15","unstructured":"Santen Pharmaceutical Co., Ltd. Santen obtains manufacturing and marketing approval in Japan for SETANEO\u00ae 0.002% ophthalmic solution, a bicyclic prostaglandin derivative that acts on FP and EP3 receptors, for treatment of glaucoma and ocular hypertension. https:\/\/www.santen.com\/en\/news\/2025\/2025_1\/20250825. Accessed 10 September 2025."},{"key":"1350_CR16","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1167\/iovs.06-0100","volume":"47","author":"T Ota","year":"2006","unstructured":"Ota T, Aihara M, Saeki T, Narumiya S, Araie M. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci. 2006;47:3395\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1350_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jop.2008.0089","volume":"25","author":"BT Gabelt","year":"2009","unstructured":"Gabelt BT, Hennes EA, Bendel MA, Constant CE, Okka M, Kaufman PL. Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009;25:1\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1350_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1167\/iovs.63.2.24","volume":"63","author":"R Yamagishi-Kimura","year":"2022","unstructured":"Yamagishi-Kimura R, Honjo M, Aihara M. The roles played by FP\/EP3 receptors during pressure-lowering in mouse eyes mediated by a dual FP\/EP3 receptor agonist. Invest Ophthalmol Vis Sci. 2022;63:24.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1350_CR19","doi-asserted-by":"publisher","first-page":"7963","DOI":"10.1167\/iovs.15-18166","volume":"56","author":"F Suto","year":"2015","unstructured":"Suto F, Rowe-Rendleman CL, Ouchi T, Jamil A, Wood A, Ward CL. A novel dual agonist of EP3 and FP receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers. Invest Ophthalmol Vis Sci. 2015;56:7963\u201370.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1350_CR20","doi-asserted-by":"publisher","first-page":"e826","DOI":"10.1097\/IJG.0000000000000449","volume":"25","author":"A Harris","year":"2016","unstructured":"Harris A, Ward CL, Rowe-Rendleman CL, Ouchi T, Wood A, Fujii A, et al. Ocular hypotensive effect of ONO-9054, an EP3\/FP receptor agonist: results of a randomized, placebo-controlled, dose escalation study. J Glaucoma. 2016;25:e826\u201333.","journal-title":"J Glaucoma"},{"key":"1350_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1136\/bjophthalmol-2015-307000","volume":"100","author":"MS Berlin","year":"2016","unstructured":"Berlin MS, Rowe-Rendleman C, Ahmed I, Ross DT, Fujii A, Ouchi T, et al. EP3\/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol. 2016;100:843\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1350_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/bjophthalmol-2016-309023","volume":"101","author":"E Miller Ellis","year":"2017","unstructured":"Miller Ellis E, Berlin MS, Ward CL, Sharpe JA, Jamil A, Harris A. Ocular hypotensive effect of the novel EP3\/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study. Br J Ophthalmol. 2017;101:796\u2013800.","journal-title":"Br J Ophthalmol"},{"key":"1350_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ogla.2025.02.004","volume":"8","author":"DL Wirta","year":"2025","unstructured":"Wirta DL, El-Harazi SM, Tepedino ME, Bacharach J. Sepetaprost 0.002% non-inferiority versus timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension: ANGEL-2. Ophthalmol Glaucoma. 2025;8:384\u201392.","journal-title":"Ophthalmol Glaucoma"},{"key":"1350_CR24","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s12325-025-03227-2","volume":"42","author":"AG Konstas","year":"2025","unstructured":"Konstas AG, Garh\u00f6fer G, L\u00fcbke J, Voykov B, Ropo A. A study of 24-h efficacy and safety of sepetaprost vs. latanoprost in patients with primary open-angle glaucoma or ocular hypertension. Adv Ther. 2025;42:3810\u201325.","journal-title":"Adv Ther"},{"key":"1350_CR25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1089\/jop.2021.0077","volume":"38","author":"DL Wirta","year":"2022","unstructured":"Wirta DL, Kuwayama Y, Lu F, Shao H, Odani-Kawabata N. Phase 2b, randomized, 3-month, dose-finding study of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: the ANGEL study. J Ocul Pharmacol Ther. 2022;38:240\u201351.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1350_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123:129\u201340.","journal-title":"Ophthalmology"},{"key":"1350_CR27","doi-asserted-by":"publisher","first-page":"1015338","DOI":"10.3389\/fphar.2022.1015338","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022;13:1015338.","journal-title":"Front Pharmacol"},{"key":"1350_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14740338.2024.2436062","volume":"24","author":"G Holl\u00f3","year":"2025","unstructured":"Holl\u00f3 G. Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opin Drug Saf. 2025;24:145\u201356.","journal-title":"Expert Opin Drug Saf"},{"key":"1350_CR29","doi-asserted-by":"publisher","unstructured":"Inatani M, Tone Y, Ikeda T, Angeles R. Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-026-01351-2 (In press)","DOI":"10.1007\/s10384-026-01351-2"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01350-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-026-01350-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-026-01350-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T05:23:06Z","timestamp":1786166586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-026-01350-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1007\/s10384-026-01350-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Inatani, Scholarship donation (Santen, Kowa, Senju, Alcon, Chugai, HOYA, Johnson & Johnson, NIDEK, Otsuka), Consulting fees (Santen, Senju), Honoraria for presentations (Santen, Kowa, Alcon, Chugai, HOYA, Johnson & Johnson, NIDEK, Otsuka, Glaukos, Viatris, Novartis, Bayer, JFC, Sandoz, Rohto, Inami), Expert testimony (Glaukos, the Japanese Pharmaceuticals and Medical Devices Agency), Advisory fee (Santen), Trustee roles for the Japan Glaucoma Society and Japanese Ophthalmological Society.; A. Kanamori, Consulting fees (Santen, Senju), Honoraria (Santen, Senju, Kowa, Otsuka, Inami, Johnson & Johnson); M. Inai, Employee (Santen); T. Ikeda, Employee (Santen); R. Angeles, Employee (Santen).","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}